AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31797473
Drug: Saffron aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron aqueous extract (SAE) (30 mg/day)
Trial: 31586644
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + aPDT (photodynamic therapy)
Trial: 29478239
Drug: PF-06669571 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06669571 (1 mg to 3 mg over 7 days)
Trial: 23113833
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Trial: 23113833
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Trial: 23113833
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of atorvastatin daily plus placebo once every 2 weeks
Trial: 23113833
Drug: SAR236553 (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR236553 (combined with atorvastatin)
Trial: 23113833
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of atorvastatin plus placebo
Trial: 18845960
Drug: Single-dose nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose nevirapine or perinatal zidovudine treatment
Trial: 15911239
Drug: Glutamine and
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine and asparagine concentrations at Day 14 in Group L
Trial: 15911239
Drug: Glutamic acid
RxNorm normalized name: Glutamic Acid
DrugBank: Glutamic acid (DB00142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamic acid amounts at Day 14 in Group L
Trial: 12621013
Drug: CCK infusion
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK infusion at 0.40 IDU/kg over 20 min
Trial: 12621013
Drug: CCK infusion
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK infusion at 0.40 IDU/kg
Trial: 30640988
Drug: Sub-hyperthermia foot
RxNorm normalized name: Fungi-Nail Toe and Foot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-hyperthermia foot bath with syndrome typing of Chinese medicine (CM), 30 min each time, once per day for 3 months
Trial: 30640988
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment of Western medicine (WM)
Trial: 30640988
Drug: Sub-hyperthermia foot
RxNorm normalized name: Fungi-Nail Toe and Foot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sub-hyperthermia foot bath with syndrome typing of Chinese medicine (CM)
Trial: 26179672
Drug: Methylprednisolone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (80 mg)
Trial: 22532661
Drug: High concentration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High concentration oxygen (8 L/min via medium concentration mask)
Trial: 15705007
Drug: Allopurinol (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (300 mg b.i.d.)
Trial: 14625517
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (10 g/day for 4 days)
Trial: 14625517
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (25 g/day for 4 days)
Trial: 14625517
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (35 g/day for 4 days)
Trial: 1892004
Drug: Cefpirome 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 0.5 g b.i.d. (1 g group)
Trial: 1892004
Drug: Cefpirome 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 1.0 g b.i.d. (2 g group)
Trial: 1892004
Drug: Ceftazidime 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 1.0 g b.i.d. (CAZ group)
Trial: 6436732
Drug: Carbohydrate intake
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate intake (rapidly or slowly absorbed sugars, given by mouth or IV injection)
Trial: 27006655
Drug: 2800 IU
RxNorm normalized name: Alendronate Sodium/Cholecalciferol 70 MG-2800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2800 IU vitamin D3 daily for eight weeks
Trial: 20528599
Drug: Long-acting beta-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta-agonists (LABAs)
Trial: 18623040
Drug: Budesonide/formoterol pMDI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol pMDI (repeated dose)
Trial: 2023417
Drug: Methotrexate 50
RxNorm normalized name: methotrexate 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 50 mg/m2
Trial: 9423749
Drug: Methotrexate 60
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 60 mg/m2
Trial: 9423749
Drug: Methotrexate 50
RxNorm normalized name: methotrexate 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 50 mg/m2 and 60 mg/m2
Trial: 8255928
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% escin gel
Trial: 3307307
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation 2,000 mg daily
Trial: 31152567
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using toluidine blue (10 mg/mL; 3 min) and a 635-nm laser (750 mW; 10 s/implant side; minimum of 60 mW/cm2)
Trial: 11996212
Drug: Metadate CD
RxNorm normalized name: Metadate CD
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metadate CD (20 mg capsule)
Trial: 11996212
Drug: Concerta (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concerta (18 mg tablet)
Trial: 11996212
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 20 mg capsules
Trial: 11996212
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 20 mg capsules
Trial: 9476972
Drug: Oral delta9-tetrahydrocannabinol
RxNorm normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral delta9-tetrahydrocannabinol (delta9-THC) 7.5 mg
Trial: 9476972
Drug: Oral delta9-tetrahydrocannabinol
RxNorm normalized name: delta9-tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral delta9-tetrahydrocannabinol (delta9-THC) 15 mg
Trial: 7666121
Drug: Pefloxacin 800
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 800 mg i.v. every 24 hours
Trial: 7666121
Drug: Pefloxacin 800
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pefloxacin 800 mg per os every 24 hours
Trial: 7666121
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg per os every 12 hours
Trial: 2698804
Drug: Methylprednisolone sodium
RxNorm normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate (MPSS) 125 mg/day intravenous for 8 weeks
Trial: 28100606
Drug: Predictive Low-Glucose
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predictive Low-Glucose Insulin Suspension (PLGS)
Trial: 25739904
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg intraventricular TPA every 12 h (five doses)
Trial: 25739904
Drug: Placebo every
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo every 12 h (five doses)
Trial: 24517060
Drug: Yishen Qingli
RxNorm normalized name: PYRROLIDINYL DIAMINOPYRIMIDINE OXIDE 33 g in 100 mL / PANAX GINSENG WHOLE 33 g in 100 mL / DIAMINOPYRIMIDINE OXIDE 30 g in 100 mL / NIACINAMIDE 33 g in 100 mL INTRADERMAL LIQUID [QINGLIN ANTI DETACHMENT NURTURING HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishen Qingli Granule (YQG) combined with low-dose Tripterygium Wilfordii multiglycoside Tablet (TWT)
Trial: 16280561
Drug: Controlling for
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlling for prior history of depression, increased life stress, and current psychoactive medication
Trial: 11573100
Drug: Bismuth subcitrate
RxNorm normalized name: BISMUTH SUBCITRATE
DrugBank: Bismuth subcitrate potassium (DB09275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bismuth subcitrate 120 mg plus metronidazole 250 mg plus tetracycline 250 mg qid plus omeprazole 20 mg bid for 7 days (OBMT)
Trial: 9400034
Drug: Amiodarone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (600 mg/day for 7 days, then 200 mg/day until discharge)
Trial: 7960359
Drug: Levamisole +
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole + topical 0.1% fluocinolone acetonide
Trial: 7960359
Drug: Levamisole +
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole + topical 0.05% clobetasol propionate
Trial: 3654034
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetropium bromide 50 mg, p.o. 3 times per day for 1 week
Trial: 3654034
Drug: Cimetropium bromide
RxNorm normalized name: cimetropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetropium bromide (exact dosage not specified)
Trial: 31724349
Drug: Nifedipine (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (control group treatment).
Trial: 26416334
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy in consecutive sessions
Trial: 22101876
Drug: Diet enriched
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet enriched with carp meat (200 g twice weekly for 4 weeks)
Trial: 19747918
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a (90 microg/week) maintenance therapy
Trial: 9631802
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine (NAC) 150 mg/kg bolus, followed by a continuous infusion of 50 mg/kg over 4 hours (n=12)
Trial: 25948208
Drug: Compound Zaofan
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Zaofan pill combined with cyclosporine and androgen
Trial: 12620132
Drug: Centrally acting
RxNorm normalized name: Other centrally acting agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrally acting antihypertensive drugs and beta‐adrenergic blockers
Trial: 12620132
Drug: Calcium‐channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐channel blocker verapamil
Trial: 8648358
Drug: HFX RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX RT with 1.2 Gy twice daily to a total dose of 69.6 Gy (n = 66)
Trial: 8648358
Drug: HFX RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFX RT with CHT consisting of 50 mg of carboplatin and 50 mg of etoposide given on each RT day (n = 65)
Trial: 1626664
Drug: Subarachnoid hyperbaric
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid hyperbaric bupivacaine 15 mg with 50 micrograms of fentanyl (group A)
Trial: 1626664
Drug: Subarachnoid hyperbaric
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid hyperbaric bupivacaine 15 mg with 25 micrograms of fentanyl (group B)
Trial: 1626664
Drug: Subarachnoid hyperbaric
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subarachnoid hyperbaric bupivacaine 15 mg with 12.5 micrograms of fentanyl (group C)
Trial: 1626664
Drug: 1 ml
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml of saline (group D)
Trial: 28382618
Drug: Bortezomib 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.6 mg/m2 intravenously on days 1, 8, 15, and 22 for four 35-day cycles
Trial: 23647281
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (ABBT and AR)
Trial: 16482646
Drug: Etanercept 50
RxNorm normalized name: etanercept 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 50 mg administered twice weekly
Trial: 16482646
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg administered twice weekly
Trial: 8127928
Drug: Moclobemide (81
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (81 patients, 100-300 mg/day)
Trial: 8127928
Drug: Tranylcypromine (79
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranylcypromine (79 patients, 10-30 mg/day)
Trial: 3038552
Drug: Blood from
RxNorm normalized name: Blood from surgical drain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood from donors without detectable CMV antibodies (CMV seronegative blood)
Trial: 27303062
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy intervention
Trial: 31362784
Drug: Buprenorphine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (8 mg per day)
Trial: 28587620
Drug: Methadone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (40 mg per day)
Trial: 21169634
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at pericardium 6 bilaterally, depth of approximately 0.7 cm, median duration of 21 min during anaesthesia, followed by acupressure wristbands for 24 h and standard treatment.
Trial: 16948927
Drug: Risperidone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1 mg/day for 6 months)
Trial: 14503797
Drug: Leuprorelin (11.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin (11.25 mg s.c. every 3 months for 2 years)
Trial: 14503797
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy (6 cycles)
Trial: 11154141
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol plus 1 mg norethisterone acetate, 1 tablet daily (HRT group)
Trial: 30172995
Drug: Phospholipid intake
RxNorm normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phospholipid intake (2.7 g/d for 6 weeks)
Trial: 23430390
Drug: Mizoribine (MZR)
RxNorm normalized name: Mizoribine
DrugBank: Mizoribine (DB12617)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine (MZR) at a starting dose of 12 mg/kg/day
Trial: 23430390
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at a starting dose of 2 g/day
Trial: 20690864
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg oral conjugated estrogens for 30 days
Trial: 16916335
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus structured education on the use of a written self-management plan and patient-initiated short courses of antibiotics and oral corticosteroids
Trial: 15315625
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg IM and normal saline IV
Trial: 15315625
Drug: Dextromethorphan (DM)
RxNorm normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (DM) 40 mg IM and tenoxicam 40 mg IV
Trial: 15315625
Drug: Chlorpheniramine maleate
RxNorm normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine maleate (CPM) 20 mg IM and normal saline IV
Trial: 17712576
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (non-operated group)
Trial: 2871788
Drug: 6-month regimen
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Trial: 2871788
Drug: 4-month regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month regimen of chemotherapy (streptomycin, isoniazid, rifampin, pyrazinamide for 2 months followed by isoniazid and rifampin)
Trial: 2871788
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 6-month series
Trial: 2871788
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with bacilli resistant to isoniazid, streptomycin, or both drugs in the 4-month series
Trial: 15822041
Drug: Oral supplement
RxNorm normalized name: Healios Oral Supplement Unflavored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral supplement enriched with fish oil, fructooligosaccharides, gum arabic, vitamin E, vitamin C, and selenium, 18 oz daily for 6 months
Trial: 15822041
Drug: Carbohydrate-based placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-based placebo formula, 18 oz daily for 6 months
Trial: 8520812
Drug: Morphine with
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine with naltrexone
Trial: 1996763
Drug: Procaine 10
RxNorm normalized name: procaine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procaine 10 mg
Trial: 1996763
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 0.5 ml (Control)
Trial: 19179917
Drug: Resorbable poly-L-lactide-co-D,L-lactide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resorbable poly-L-lactide-co-D,L-lactide (PLDLLA) cage
Trial: 17690198
Drug: beta-alanine (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta-alanine (4.8 g/day)
Trial: 9043028
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin 3 (rhIL‐3) 10 microg kg(‐1) day(‐1) (days 5‐9) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7‐16)
Trial: 9043028
Drug: Paclitaxel (135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (135 mg m(‐2) day 1), ifosfamide (1.2 g m(‐2) day(‐1) days 2-4), cisplatin (30 mg m(‐2) day(‐1) days 2-4) + G‐CSF 5.0 microg kg(‐1) day(‐1) (days 7-16)
Trial: 7639381
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of 2% lidocaine IV as a bolus (Group B)
Trial: 7639381
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg of 2% lidocaine IV for 5 min (Group C)
Trial: 7639381
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg of 2% lidocaine IV for 5 min (Group D)
Trial: 7639381
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg of 1.5% lidocaine epidurally as a bolus (Group E)
Trial: 3235818
Drug: Alpidem (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpidem (50 mg)
Trial: 3235818
Drug: Alpidem (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpidem (25 mg)
Trial: 3235818
Drug: Alcohol +
RxNorm normalized name: Benzyl alcohol + eucalyptus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol + Alpidem (50 mg)
Trial: 3235818
Drug: Alcohol +
RxNorm normalized name: Benzyl alcohol + eucalyptus oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol + Alpidem (25 mg)
Trial: 26659384
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl injection
Trial: 25149384
Drug: Yinxieling decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinxieling decoction (8 weeks treatment)
Trial: 23129602
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 350 mg
Trial: 23129602
Drug: AMG 145
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 145 420 mg
Trial: 16022920
Drug: Topotecan 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 1.25 mg/(m² day) IV days 1-5, cisplatin 50 mg/m² IV day 5 (T/C)
Trial: 16022920
Drug: Topotecan 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan 0.75 mg/(m² day) IV days 1-5, etoposide 60 mg/(m² day) IV days 1-5 (T/E)
Trial: 12675729
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of elemental Fe per day
Trial: 11199506
Drug: PDE III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDE III inhibitor (amrinone, 1 mg/kg)